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Sitagliptin induced splenic infarcts 
ABSTRACT 
Sitagliptin belongs to the class of dipeptidyl pepti-
dase-4 (DPP-4) inhibitors. DPP-4 inhibitors are remark-
ably well tolerated oral antihyperglycemic drugs with 
an adverse effect profile similar to that of placebo. No 
adverse effects have been reported even with overdose 
of sitagliptin in suicide attempts. We present here case 
summary of a 35-year-old female with type 2 diabetes 
mellitus and major depressive disorder who presented 
with multiple splenic infarcts after ingestion of sitag-
liptin 700 mg and metformin 14 g with suicidal intent. 
To the best of our knowledge, there are no published 
reports of splenic infarcts as an adverse event of sit-
agliptin. (Clin Diabetol 2017; 6, 6: 215–217)
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Introduction
Sitagliptin belongs to the class of dipeptidyl pepti-
dase-4 (DPP-4) inhibitors. DPP-4 inhibitors are remark-
ably well tolerated oral antihyperglycemic drugs with an 
adverse effect profile similar to that of placebo [1]. The 
other advantages with this class include that they are 
weight neutral and hypoglycemia is rare [1]. Although 
the currently available DPP-4 inhibitors are thought to 
be highly selective, continued long-term surveillance for 
unexpected adverse events is essential. The multiplicity 
of substrates and peptide fragments whose biology 
DPP-4 inhibitors affect imparts complexity to the bio-
logy of these agents [2]. 
We present here case summary of a 35-year-old 
female with type 2 diabetes mellitus (T2DM) and ma-
jor depressive disorder who presented with multiple 
splenic infarcts after ingestion of sitagliptin 700 mg and 
metformin 14 g with suicidal intent (7 times greater 
than the approved maximum daily dose of sitagliptin 
and over 5 times the approved maximum daily dose of 
metformin). To the best of our knowledge, there are 
no published reports of splenic infarcts as an adverse 
event of sitagliptin.
Case study 
A 35-year-old normotensive female, known to have 
T2DM for last 11 years and major depressive disorder 
presented with severe left upper quadrant pain accom-
panied by pleuritic chest pain and left shoulder pain 
of few days duration. The pain was associated with 
nausea and vomiting. She was conscious and alert. 
Her blood pressure was 140/80 mm Hg. Abdominal 
examination revealed left upper quadrant tenderness. 
Her medications included 2 doses of premixed insulin, 
a fixed — dose combination pill of sitagliptin 50 mg 
and metformin 1000 mg, levothyroxine 50 mg and 
escitalopram 20 mg. She had been on sitagliptin for 
last 2 years and on insulin for last 8 months. She had 
poor glycemic control as reflected by HbA1c of 8.5% and 
fasting plasma glucose of 200 mg/dL and postprandial 
glucose of 320 mg/dL. Baseline investigations including 
complete blood counts, hematocrit, ESR, kidney and 
liver function tests were unremarkable; total platelet 
count was 2.2 lacs/mm3. Serum amylase was normal. 
Ultrasonography abdomen was normal. Pain was man-
aged with analgesics and she was advised to report 
back in case of persistence/worsening of symptoms. 
Patient reported back two days later with worsening of 
pain. On further revision of history, she admitted that 
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she had taken 14 fixed-dose combination pills con-
taining sitagliptin 50 mg + metformin 1000 mg each, 
amounting to a total ingestion of sitagliptin 700 mg 
and metformin 14 g with suicidal intent one day prior 
to the development of symptoms.
For further evaluation of her symptoms, contrast 
enhanced computed tomography (CECT) of the abdo-
men was performed which revealed multiple fairly 
well defined hypodense lesions in spleen without any 
significant enhancement suggestive of splenic infarcts 
with bilateral minimal basal atelectasis (Fig. 1A and B). 
CECT also revealed minimal fluid and fat strandings 
posteroinferior to spleen. Serum pH was normal as was 
serum lactate levels. A detailed clinical and investigative 
work up was undertaken to find any possible etiology 
of splenic infarcts. There was no clinical suggestion of 
the presence of underlying hematological, thrombo-
embolic or collagen vascular disease. The patient had 
never taken estrogens. Echocardiography did not reveal 
any evidence of valvular lesion or endocarditis. The 
D-dimer test and antinuclear antibody were negative. 
Coagulogram was normal. Serum protein C, protein S, 
homocysteine levels were normal. The serology for 
hepatitis C was negative. The work up for anti-phos-
pholipid antibody syndrome (lupus anticoagulant, anti-
phospholipid antibodies IgG and IgM, dilute Russell 
Viper Venom test) was negative. 
A clear temporal relation between ingestion of 
“large doses” of sitagliptin and development of splenic 
infarcts together with negative results in the work up for 
any known etiologies of splenic infarct strongly incrimi-
nate sitagliptin as the cause for splenic infarcts in our 
patient. Patient was taken off sitagliptin and the other 
medications were continued. Her management included 
hydration, analgesics, and frequent monitoring. After 
few days her symptoms abated and she was completely 
asymptomatic a week later. A repeat CECT abdomen 
could not be undertaken as the patient declined it.
Discussion 
The adverse effect profile DPP-4 inhibitors is similar 
to that of placebo and no adverse effects have been 
reported even with overdose of DPP-4 inhibitors [3, 4]. 
Furukawa et al., reported no adverse effects in 
a 86-year-old woman with type 2 diabetes and depres-
sion, after ingestion of 1,700 mg of sitagliptin (17 
times greater than the approved maximum daily dose) 
with suicidal intent [3]. In another reported case, an 
overdose of sitagliptin 3500 mg (35 times greater than 
the approved maximum daily dose) did not lead to any 
adverse events [4]. This is the highest reported case for 
sitagliptin overdose. These two published reports reflect 
that “large doses” of sitagliptin do not lead to any 
adverse events. Our patient developed splenic infarcts 
with 700 mg of sitagliptin; this may reflect individual 
vulnerability to an adverse event with this drug.
An eHealthMe based on reports of 41.491 persons 
who had side effects with sitagliptin, updated on 25th 
Jul, 2017 from FDA, reported splenic infarction in 13 
persons (0.03%) [5]. Splenic infarction was reported 
especially in males, those who had been taking the drug 
for 2 to 5 years, with concomitant use of exenatide and 
having essential hypertension. In this report all patients 
were 60 years of age or older [5].
The mechanism of sitagliptin induced splenic in-
farcts is unknown. Thrombosis may be induced with 
Figure 1. Contrast enhanced computed tomography of the abdomen showing multiple splenic infarcts (arrows)
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inhibition of DPP-4 activity. DPP-4, also known as CD26, 
is expressed by microvascular endothelial cells in hu-
mans (i.e. in liver, spleen, lungs and brain) and in the 
hearts of rats [6, 7]. DPP-4 has the potential to inhibit 
fibrin polymerization and clot formation [8, 9]. Thus 
DPP-4 may behave as an immobilized anti-coagulant 
on microvascular endothelium and possesses anti-
thrombotic properties; decreased DPP-4 expression and 
activity has been found to coincide with an increase in 
Tissue Factor expression and induction of in situ throm-
bosis [10]. Inhibition of DPP-4 activity also induces 
adhesion of platelets; this may be another mechanism 
of thrombosis which occurs with inhibition of DPP-4 
activity [10]. For two reasons we strongly believe that 
metformin was not responsible for splenic infarcts in 
our patient. Firstly, metformin has never been reported 
to cause splenic infarction or infarction of any other 
viscera. Secondly, metformin has not been reported to 
have any unfavourable effect on fibrin polymerization, 
coagulation and platelets.
Our patient was a young female, had been on sitag-
liptin for 2 years only, was normotensive and had never 
been on exenatide. To the best of our knowledge this 
is the first published case report of sitagliptin induced 
splenic infarcts. Our case highlights that abdominal 
pain in a patient on sitagliptin may indicate the pres-
ence of splenic infarcts and deserves thorough evalua-
tion and management. In addition our case emphasizes 
that splenic infarcts due to sitagliptin phosphate may 
occur in young individuals without other risk factors 
like essential hypertension and the concomitant use 
of exenatide. 
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